AbbVie Inc. $ABBV is Bill Few Associates Inc.’s 7th Largest Position

Bill Few Associates Inc. raised its stake in AbbVie Inc. (NYSE:ABBV) by 22.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,883 shares of the company’s stock after buying an additional 7,805 shares during the period. AbbVie comprises about 2.4% of Bill Few Associates Inc.’s investment portfolio, making the stock its 7th biggest position. Bill Few Associates Inc.’s holdings in AbbVie were worth $9,570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in ABBV. Vanguard Group Inc. grew its position in AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares in the last quarter. Norges Bank purchased a new stake in AbbVie during the second quarter valued at about $4,288,200,000. Legal & General Group Plc raised its position in AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares in the last quarter. Wellington Management Group LLP lifted its stake in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Finally, Amundi lifted its stake in AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. UBS Group dropped their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑1 obesity data for ABBV‑295: AbbVie reported dose‑dependent, meaningful weight loss from ABBV‑295 (a long‑acting amylin analog), marking the company’s formal entry into the anti‑obesity market and diversifying revenue beyond immunology and oncology — a potentially material long‑term growth driver if later‑stage trials succeed. AbbVie’s ABBV-295 Obesity Data Opens New Non Incretin Opportunity
• Positive Sentiment: Multi‑year MLB partnership expands “Striking Out Cancer” nationally: AbbVie was named the Official Pharmaceutical Partner of Major League Baseball, amplifying its cancer‑support initiative, broadening brand reach and CSR impact (each MLB strikeout triggers donations to Stand Up To Cancer). This raises AbbVie’s consumer visibility and may help patient‑facing positioning. AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire) MLB: AbbVie named official pharmaceutical partner
• Positive Sentiment: Recent fundamentals and legal risk reduction support the story: AbbVie beat top‑line estimates in its latest quarter, raised FY‑2026 guidance, and a Bloomberg Law report shows the company prevailed in a worker’s suit over family‑medical‑history queries — reducing a potential legal overhang. These items support earnings visibility and dividend stability. AbbVie to sponsor leading US baseball league AbbVie beats worker’s suit (Bloomberg Law)
• Neutral Sentiment: Positive media/analyst commentary on valuation: Several outlets (The Motley Fool, Kalkine) highlight AbbVie’s dividend, revenue growth and argue the stock looks attractively valued, which may support longer‑term investor interest but is not an immediate catalyst. Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now AbbVie Shares Rise on Revenue Growth (Kalkine)
• Negative Sentiment: Valuation and technical/financial quirks may limit near‑term upside: AbbVie trades below its 50‑ and 200‑day moving averages and shows a high reported P/E (~86.8) and a negative ROE figure (accounting effect), factors that can pressure sentiment and constrain multiple expansion until growth visibility improves. MarketBeat ABBV snapshot

AbbVie Trading Down 0.0%

ABBV opened at $204.86 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The business’s 50-day moving average price is $222.48 and its 200-day moving average price is $224.74. The company has a market cap of $362.23 billion, a P/E ratio of 86.81, a P/E/G ratio of 0.71 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the business posted $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.